The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC).
D. Adelberg
No relevant relationships to disclose
A. B. Apolo
No relevant relationships to disclose
R. A. Madan
No relevant relationships to disclose
J. L. Gulley
No relevant relationships to disclose
A. Pierpoint
No relevant relationships to disclose
D. R. Kohler
No relevant relationships to disclose
J. B. Trepel
No relevant relationships to disclose
S. M. Steinberg
No relevant relationships to disclose
D. Price
No relevant relationships to disclose
B. R. Leigh
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
C. P. Theuer
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
W. D. Figg
No relevant relationships to disclose
W. L. Dahut
No relevant relationships to disclose